Prepared By R.R. Donnelley Financial -- Form 8-K
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
 
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  08/05/2008
 
ACADIA Pharmaceuticals Inc.
(Exact name of registrant as specified in its charter)
 
Commission File Number:  000-50768
 
Delaware
  
06-1376651
(State or other jurisdiction of
  
(IRS Employer
incorporation)
  
Identification No.)
 
3911 Sorrento Valley Boulevard
San Diego, CA 92121
(Address of principal executive offices, including zip code)
 
(858) 558-2871
(Registrant’s telephone number, including area code)
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
Item 2.02.    Results of Operations and Financial Condition
 
On August 5, 2008, ACADIA Pharmaceuticals Inc. issued a press release announcing its financial results for the second quarter and three months ended June 30, 2008. A copy of this press release is furnished herewith as Exhibit 99.1. Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.
 
 
Item 9.01.    Financial Statements and Exhibits
 
(d) The following exhibit is furnished erewith:

   

99.1    Press release dated August 5, 2008
 

 

Signature(s)
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
      
 
ACADIA Pharmaceuticals Inc.
 
 
Date: August 05, 2008
     
By:
 
/s/    Thomas H. Aasen
               
Thomas H. Aasen
               
Vice President, Chief Financial Officer, Treasurer, and Secretary
 
 

 

Exhibit Index
 
Exhibit No.
  
Description
EX-99.1
  
Press Release Dated August 5, 2008